Short stature. Disorders resulting from impaired renal tubular function
Conditions
Interventions
Intervention 1: ?First intervention group: In this group, patients (N = 25) receive injection of growth hormone (Genotropin manufactured by Pfizer, US) from the beginning of short stature, at the ra
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
3 Years to 7 Years
Inclusion criteria
Inclusion criteria: Patient and parent consent to participate in the study. Patients with chronic kidney disease (CKD). Patients must be girls. With short stature (height and growth velocity respectively below 3th and 25th percentile for more than 1 year). In all patients, beginning of dialysis around 3.5 to 5 years. Growth hormone has been started in all patients from the age of 5.5 to 8 years, despite therapeutic indications.
Exclusion criteria
Exclusion criteria: Incidence puberty before the estrogen therapy Kidney transplantation before the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Final height after 15 years old. Timepoint: Before the intervention and after the age of 15. Method of measurement: Height gauge. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone density. Timepoint: Before the intervention and after the age of 15. Method of measurement: Dexa bone densitometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDavod Amirkashani
Iran University of Medical Sciences
Outcome results
None listed